Cargando…
A Review on MS-Based Blood Biomarkers for Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of neurodegenerative dementia and there is no cure to date. Biomarkers in cerebrospinal fluid (CSF) are already included in the diagnostic work-up of symptomatic patients but markers for preclinical diagnosis and disease progression are not available....
Autores principales: | Oeckl, Patrick, Otto, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908529/ https://www.ncbi.nlm.nih.gov/pubmed/31833028 http://dx.doi.org/10.1007/s40120-019-00165-4 |
Ejemplares similares
-
Blood‐based biomarkers for Alzheimer's disease
por: Leuzy, Antoine, et al.
Publicado: (2021) -
Blood-based molecular biomarkers for Alzheimer’s disease
por: Zetterberg, Henrik, et al.
Publicado: (2019) -
CSF Ubiquitin Levels Are Higher in Alzheimer’s Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease
por: Abu-Rumeileh, Samir, et al.
Publicado: (2020) -
Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer’s and other neurodegenerative diseases
por: Halbgebauer, Steffen, et al.
Publicado: (2022) -
Advances in blood-based protein biomarkers for Alzheimer's disease
por: Clark, Lorraine Fuhrmann, et al.
Publicado: (2013)